Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab versus aflibercept in diabetic macular edema
NL-OMON50742Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brolucizumab and aflibercept in diabetic macular edema (DME), sponsored by Novartis. Primary endpoint: Change from baseline in best corrected visual acuity at Week 52. Started Nov 2018; status: active, not recruiting.
02
Drugs
brolucizumabaflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NL-OMON50742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50742.